`_______________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`_______________
`
`AMERIGEN PHARMACEUTICALS LIMITED
`
`and
`
`ARGENTUM PHARMACEUTICALS LLC,
`
`Petitioners
`
`v.
`
`JANSSEN ONCOLOGY, INC.,
`
`Patent Owner
`_______________
`
`Case IPR2016-002861
`
`Patent 8,822,438 B2
`_______________
`
`
`
`PETITIONERS’ OPPOSITION TO PATENT OWNER’S
`
`MOTION TO EXCLUDE EVIDENCE
`
`
`
`
`
`
`
`1 Case IPR2016-01317 has been joined with this proceeding.
`
`
`
`Petitioners’ Opposition To Patent Owner’s Motion To Exclude Evidence
`Petition for Inter Partes Review 2016-00286
`
`
`
`
`Petitioners, Amerigen Pharmaceuticals Limited and Argentum
`
`Pharmaceuticals LLC, oppose Patent Owner’s, Janssen Oncology, Inc., Motion to
`
`Exclude Evidence submitted by Petitioners.
`
`I. Declarations and related Exhibits of Deforest McDuff (economic
`
`expert).
`
`
`
`Patent Owner argues that all the evidence submitted by Petitioners
`
`concerning commercial success should be excluded. As Patent Owner correctly
`
`points out, commercial success can be relevant to the issue of obviousness of a
`
`patent claim. In this instance, the Patent Owner itself attempted to claim
`
`commercial success as an objective indicia of non-obviousness in Patent Owner’s
`
`Response. (See Patent Owner’s Response at p. 60).
`
`There is no basis in law or common sense suggesting that Patent Owner can
`
`attempt to establish non-obviousness with evidence of commercial success in the
`
`course of prosecuting a patent, and then again during an IPR proceeding, but that
`
`Petitioners are prohibited from addressing such, commenting upon, and offering its
`
`own evidence on the issue. Tellingly, Patent Owner cites to no regulation or case
`
`law on the issue.
`
`Patent Owner’s issue with Dr. McDuff’s first declaration (Exh. 1017) seems
`
`to be that it was offered prior in time to Patent Owner’s Response and is therefore
`
`not technically a “rebuttal.” Dr. McDuff’s first declaration was necessitated by the
`
`2
`
`
`
`Petitioners’ Opposition To Patent Owner’s Motion To Exclude Evidence
`Petition for Inter Partes Review 2016-00286
`
`
`
`
`original prosecution record leading to the issuance of the ‘438 Patent in the first
`
`instance. Patent Owner overlooks that critically, in the case of the ‘438 Patent,
`
`patentees were only able to overcome compelling prior art rejections based on
`
`“commercial showings.” Dr. McDuff’s Declaration necessarily addresses the
`
`original prosecution record. Patent Owner cannot expect Petitioners and the Board
`
`to not consider the grounds on which the ‘438 patent issued in the first instance.
`
`Again, Patent Owner offers no case law to support this notion that such evidence
`
`must be offered in the Reply as opposed to the Petition itself.
`
`Finally, Patent Owner claims that Dr. McDuff’s second declaration
`
`(currently labeled Exh. 1152) is not cited in Petitioners’ Reply. As is known to the
`
`Patent Owner, Dr. McDuff’s second declaration was inadvertently labeled as
`
`Exhibit 1152. However, the second McDuff Declaration is cited as Exhibit 1096 in
`
`Petitioners’ Reply brief and Exhibits 1149, 1150, 1151 and 1190 are cited in the
`
`second McDuff declaration. Petitioners have approached the Board to correct the
`
`clerical error. There has been no prejudice to Patent Owner in this regard, as
`
`counsel fully considered Dr. McDuff’s second declaration and exhibits, and indeed
`
`deposed him on it. Exh. 1191. During the deposition of Dr. McDuff the Patent
`
`Owner did not make any objections that the testimony was irrelevant. It is illogical
`
`3
`
`
`
`Petitioners’ Opposition To Patent Owner’s Motion To Exclude Evidence
`Petition for Inter Partes Review 2016-00286
`
`
`
`
`that Patent Owner has objected to Dr. McDuff’s Declaration but did not object to
`
`Dr. McDuff’s deposition based upon his declaration.
`
`II. Certain of Petitioners’ Exhibits to Its Reply Brief Filed and
`
`Served After Midnight.
`
`
`
`Patent Owner admits that Petitioners’ Reply brief and four expert
`
`declarations accompanying its Reply brief were timely filed but complains that the
`
`exhibits were filed after midnight. Patent Owner relies solely on Teva
`
`Pharmaceuticals USA, Inc. v. Monosol RX, LLC, IPR2016- 00281, -00282, Papers
`
`21 and 19 (PTAB May 23, 2016) for the notion that the exhibits should be stricken.
`
`Patent Owner fails to mention that Teva however missed a statutory bar for the
`
`filing of a Petition. There is no such bar here, and in the interest of justice the
`
`exhibits should not be stricken.
`
`The Patent Owner does not make an actual claim of prejudice and there was
`
`none. First, Petitioners note that January 16, 2017 was a national holiday, the
`
`USPTO was officially closed, and Patent Owner received all exhibits prior to open
`
`of business on the morning of the first business day following the holiday. Second,
`
`the Patent Owner took all of the depositions of Petitioners’ experts as scheduled.
`
`Patent Owner did not request additional time to prepare or otherwise object until
`
`after it took each of the depositions. Further, Patent Owner elected not to use more
`
`than half of its allotted time for each deposition.
`
`4
`
`
`
`Petitioners’ Opposition To Patent Owner’s Motion To Exclude Evidence
`Petition for Inter Partes Review 2016-00286
`
`
`
`
`Finally, Patent Owner’s subtle suggestion of gamesmanship is unwarranted.
`
`Petitioners experienced technical problems during the filing which caused the
`
`delay. Petitioners have always cooperated with Patent Owner including giving
`
`Patent Owner two extensions totaling approximately five weeks (August 31 to
`
`October 4) to file its Preliminary Response and working with Patent Owner to
`
`schedule depositions of the four experts relied upon in Petitioners’ Reply in
`
`advance of filing the Reply. With regard to the five hour delay in filing the
`
`exhibits to the Petitioners’ Reply, Petitioners, in response to Patent Owner’s
`
`Objection served on January 23, 2017, have requested that the Patent Owner
`
`stipulate to an extension of the deadline from January 16 to January 17 but Patent
`
`Owner rejected such a stipulation.
`
`III. Paragraphs of Petitioners’ Reply Declarations Not Explicitly
`
`Recited in Petitioners’ Reply.
`
`
`
`Patent Owner, citing no statute, regulation, or case law, complains that any
`
`paragraph of an expert declaration not explicitly cited in Petitioners’ Reply brief
`
`should be stricken. There is simply no legal basis for striking these paragraphs.
`
`Patent Owner’s sole basis for arguing irrelevance is the lack of citation in the
`
`Reply brief. Patent Owner did not examine the substance of any paragraphs it
`
`moved to exclude. That is, Patent Owner failed to consider that the paragraphs at
`
`5
`
`
`
`Petitioners’ Opposition To Patent Owner’s Motion To Exclude Evidence
`Petition for Inter Partes Review 2016-00286
`
`
`
`
`issue are relevant to the portions of the expert declarations that are cited in the
`
`Reply brief.
`
`It is extremely common for expert declarations to contain information that is
`
`not directly cited in a party’s brief. Expert declarations almost always contain
`
`information relevant to the expert’s opinions that are not cited by paragraph
`
`number in the brief. In fact, Patent Owner’s own expert declarations are replete
`
`with paragraphs that are not cited in Patent Owner’s own Response brief.
`
`With regard to Dr. McDuff’s second declaration, as explained above, this
`
`was inadvertently labeled as Exhibit 1152. However, the second McDuff
`
`Declaration is cited as Exhibit 1096 in Petitioners’ Reply brief. Patent Owner has
`
`denied Petitioners’ request to correct this clerical error. Patent Owner has denied
`
`this request in spite of Petitioners previous consent for Patent Owner to correct not
`
`just clerical errors, but changes more substantive in nature to its own expert’s
`
`declaration. Accordingly Petitioner has approached the Board to correct the
`
`clerical error.
`
`
`
`IV. Petitioners Exhibits Objected to Due to Lack of Authenticity and
`
`Hearsay.
`A. Authenticity
`
`
`Patent Owner initially objected to Exhibits 1040, 1041, 1048, 1049, 1051-
`
`1053, 1055-1057, 1088, 1128, 1130, 1140, and 1166 as lacking authenticity.
`
`6
`
`
`
`Petitioners’ Opposition To Patent Owner’s Motion To Exclude Evidence
`Petition for Inter Partes Review 2016-00286
`
`
`
`
`Petitioner timely responded to each objection and timely served supplemental
`
`evidence authenticating each of these exhibits2. In particular, Petitioners provided
`
`the declarations of DeForest McDuff and Scott Serels as Exhibits 1068 and 1069,
`
`respectively, that authenticated the objected-to exhibits. Yet, in its motion, Patent
`
`Owner fails to identify any alleged deficiency in the authentication contained in the
`
`supplemental evidence (or address the supplemental evidence at all).
`
`Patent Owner similarly complains that Exhibits 1017 [B-1 and B-2], 1032,
`
`1042-1044, 1058-1063, 1067, and 1140 lack authentication. Again, Petitioners
`
`timely responded to each objection and timely served supplemental evidence
`
`authenticating each of these exhibits.3 In particular, Petitioners provided the
`
`declarations of DeForest McDuff, Scott Serels, and Jayesh Bindra as Exhibits
`
`1068, 1069 and 1070, respectively, authenticating the exhibits. In its motion,
`
`Patent Owner again failed to identify any the alleged deficiency in the
`
`authentication contained in the supplemental evidence (or address the supplemental
`
`evidence at all).
`
`
`
`2 Due to the schedule Petitioners will timely file supplemental evidence
`authenticating Exhibits 1088, 1128, 1130, 1140, and 1166.
`
` 3
`
` Due to the schedule Petitioners will timely file supplemental evidence
`authenticating Exhibit 1140.
`
`7
`
`
`
`Petitioners’ Opposition To Patent Owner’s Motion To Exclude Evidence
`Petition for Inter Partes Review 2016-00286
`
`
`
`
`For example, Patent Owner complains that Exhibit 1032, “purports to be the
`
`‘Taxotere® Prescribing Information’, but this exhibit lacks proper authentication
`
`and foundation at least because the circumstances surrounding the source and the
`
`accuracy of the ‘Taxotere® Prescribing Information’ have not been established.”
`
`Yet the declaration of Scott Serels describes in detail where the document is found
`
`on the Food and Drug Administration website and swears it is a true and correct
`
`copy of such document. See Exh. 1069 at 7.
`
`Patent Owner makes similar complaints about the other documents while
`
`seemingly ignoring the Petitioners’ supplemental evidence, i.e., Exhibits 1068,
`
`1069 and 1070. Instead Patent Owner makes general conclusory statements about
`
`Petitioners’ exhibits while failing to address the actual statements in Petitioners’
`
`declarations. Tellingly, the supplemental evidence provided by Patent Owner to
`
`authenticate exhibits provides less information than Petitioners have provided in
`
`their supplemental evidence.
`
`B. Hearsay
`
`Patent Owners assert that Exhibits 1042-1044, 1055, 1056, 1058-1063, and
`
`1067 are hearsay. All the objected to exhibits fall into an exception under Federal
`
`Rules of Evidence 803.
`
`8
`
`
`
`Petitioners’ Opposition To Patent Owner’s Motion To Exclude Evidence
`Petition for Inter Partes Review 2016-00286
`
`
`
`
`Patent Owner objects to Exhibits 1042-1044, 1056, and 1058-1063 and
`
`correctly characterize these as investment analyst reports. These documents
`
`clearly fall within the exception to the hearsay Rule 803(17), which states:
`
`“Market Reports and Similar Commercial Publications. Market quotations, lists,
`
`directories, or other compilations that are generally relied on by the public or by
`
`persons in particular occupations.” Dr. McDuff relied on these commercial
`
`publications as a person in the occupation of consulting in applied business
`
`economics. Dr. McDuff explicitly identifies these documents as research material
`
`in his Declaration (Exh. 1017, attachment A2). Patent Owner fails to prove or
`
`even argue that the documents are not generally relied on by the public or by
`
`persons in Dr. McDuff’s occupational field.
`
`Additionally, Exhibits 1055 and 1067 are similarly reports of the type
`
`generally relied on by persons in Dr. McDuff’s occupation. For example, Patent
`
`Owner’s own economics expert, Dr. Christopher Vellturo, relied on both
`
`documents in the formation of his opinion. See Exh. 2044, Appendix A. Further,
`
`while Dr. Vellturo’s declaration purports to evaluate Dr. McDuff’s analysis, Dr.
`
`Vellturo failed to assert that any of the objected to exhibits were not generally
`
`relied on by the public or by persons in particular occupations.
`
`None of the exhibits should be excluded as hearsay.
`
`9
`
`
`
`Petitioners’ Opposition To Patent Owner’s Motion To Exclude Evidence
`Petition for Inter Partes Review 2016-00286
`
`
`
`
`
`
`
`
`Dated: February 3, 2017
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Respectfully Submitted,
`
`/William D. Hare/
`William D. Hare
`Reg. No. 44,739
`McNeely Hare & War, LLP
`12 Roszel Road, Suite C104
`Princeton, NJ 08540
`(202) 640-1801
`bill@miplaw.com
`
`10
`
`
`
`Petitioners’ Opposition To Patent Owner’s Motion To Exclude Evidence
`Petition for Inter Partes Review 2016-00286
`
`
`
`
`
`
`CERTIFICATE OF SERVICE
`
`The undersigned hereby certifies that the foregoing Petitioners’ Opposition
`
`to Patent Owner’s Motion to Exclude Evidence was served on February 3, 2017 by
`
`delivering copies via electronic mail on the following attorneys of record for the
`
`Patent Owner:
`
`Dianne B. Elderkin
`Barbara L. Mullin
`Ruben H. Munoz
`delderkin@akingump.com
`bmullin@akingump.com
`rmunoz@akingump.com
`JANS-ZYTIGA@akingump.com
`AKIN GUMP STRAUSS HAUER & FELD LLP
`
`David T. Pritikin
`Bindu Donovan
`Paul J. Zegger
`Todd Krause
`Isaac Olson
`Alyssa B. Monsen
`dpritikin@sidley.com
`bdonovan@sidley.com
`pzegger@sidley.com
`tkrause@sidley.com
`iolson@sidley.com
`amonsen@sidley.com
`ZytigaIPRTeam@sidley.com
`SIDLEY AUSTIN LLP
`
`Jennifer H. Roscetti
`Anthony C. Tridico
`jennifer.roscetti@finnegan.com
`anthony.tridico@finnegan.com
`FINNEGAN HENDERSON FARABOW GARRETT & DUNNER
`
`11
`
`
`
`Petitioners’ Opposition To Patent Owner’s Motion To Exclude Evidence
`Petition for Inter Partes Review 2016-00286
`
`
`
`
`
`
`
`Teresa Stanek Rea
`Shannon M. Lentz
`TRea@Crowell.com
`SLentz@Crowell.com
`CROWELL & MORING LLP
`
`
`Date: February 3, 2017
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`/William D. Hare/
`William D. Hare
`
`12
`
`